<i>EGFR</i>Mutations in US Hispanic Versus Non-Hispanic White Patients With Lung Adenocarcinoma

Zhang, Wei; McQuitty, Elizabeth; Olsen, Randall J.; Fan, Hongxin; Hendrickson, Heather; Tio, Fermin O.; Newton, Keith; Cagle, Philip T.; Jagirdar, Jaishree

doi:10.5858/arpa.2013-0311-oa

Cited by 16 publications

(16 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, it partially explains the paucity of tumor-specific molecular characterization data in Latinos and other minority populations in the United States. In this particular case, although the first reports of the frequency of EGFR mutations in NSCLC in the United States date back to 2004, 17 the initial report for Latinos in the United States came almost a decade later, 11 and the total number of reports and patients tested by race or ethnicity differs significantly between majority and minority populations. Of utmost importance is that in the event the cancer molecular profile of a particular minority population would differ significantly from the majority, such a disparity in molecular data availability could lead to the worsening of the already existing outcome disparities among patients of different races or ethnicities in the United States.…”

Section: Discussionmentioning

confidence: 89%

“…Published reports have been limited to retrospective cohorts that are constrained, among other factors, by patient selection for mutation testing based on clinical characteristics. 10,11 …”

Section: Introductionmentioning

confidence: 99%

“…Lung cancer incidence rates are lower among Latinos 13 ; however, despite the lower socioeconomic status, more limited access to care, and diagnoses at advanced stages of disease that would predict otherwise, lung cancer mortality rates are 50% lower among Latinos than non-Latino whites. 13,14 Although this so-called Latino paradox is still a matter of debate, given the limited reports to date, 10,11 there is a clear need for a more comprehensive molecular characterization of NSCLC in this ethnic group to better understand outcome disparities in the United States. In particular, patients with EGFR mutations are known to have better survival than patients with wild-type EGFR .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

EGFR Mutations in Latinos From the United States and Latin America

López-Chávez

Thomas

Evbuomwan

et al. 2016

JGO

View full text Add to dashboard Cite

PurposeEpidermal growth factor receptor (EGFR) mutations confer sensitivity to EGFR tyrosine kinase inhibitors in patients with advanced non–small-cell lung cancer (NSCLC). There are limited and conflicting reports on the frequency of EGFR mutations in Latinos.Patients and MethodsSamples from 642 patients with NSCLC from seven institutions in the United States and Latin America were assessed for EGFR mutations (exons 18 to 21) at Clinical Laboratory Improvement Amendments-certified central laboratories.ResultsEGFR mutation analysis was successfully performed in 480 (75%) of 642 patients; 90 (19%) were Latinos, 318 (66%) were non-Latino whites, 35 (7%) were non-Latino Asians, 30 (6%) were non-Latino blacks, and seven (2%) were of other races or ethnicities. EGFR mutations were found in 21 (23%) of 90 Latinos with varying frequencies according to the country of origin; Latinos from Peru (37%), followed by the United States (23%), Mexico (18%), Venezuela (10%), and Bolivia (8%). In never-smoker Latinos and Latinos with adenocarcinoma histology, EGFR mutation frequencies were 38% and 30%, respectively. There was a significant difference in the frequency of EGFR mutations among the different racial and ethnic subgroups analyzed (P < .001), with non-Latino Asians having the highest frequency (57%) followed by Latinos (23%), non-Latino whites (19%), and non-Latino blacks (10%). There was no difference between Latinos (23%) and non-Latinos (22%; P = .78) and Latinos and non-Latino whites (P = .37). Patients from Peru had an overall higher frequency of mutations (37%) than all other Latinos (17%), but this difference only exhibited a trend toward significance (P = .058).ConclusionThere was no significant difference between the frequency of EGFR mutations in NSCLC in Latinos and non-Latinos.

show abstract

Section: Discussionmentioning

confidence: 89%

“…Published reports have been limited to retrospective cohorts that are constrained, among other factors, by patient selection for mutation testing based on clinical characteristics. 10,11 …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

EGFR Mutations in Latinos From the United States and Latin America

López-Chávez

Thomas

Evbuomwan

et al. 2016

JGO

View full text Add to dashboard Cite

show abstract

“…In contrast, several studies have reported a lower incidence of EGFR mutations among H/L (Table 1), but only one of these studies is from LA [34], where they found 8.1% frequency in Argentinian patients, and it can be speculated that this could be related to the high European/Caucasian migration to Argentina, which is in contrast to the Japanese migration to Peru. The other studies reporting no difference between H/L and WNH in the incidence of EGFR mutations are either from H/L living in the USA [18, 35], or in Spain [36, 37]. It is important to note, that in more recent studies looking at EGFR mutations in Spain, the rate of mutations is 24.6% [38].…”

Section: Hispanics/latinos and Lung Cancermentioning

confidence: 99%

“…The frequency of EGFR mutations has been extensively studied in some groups and determined to be approximately 30% for Asian populations, 15% for WNH, and 19% for AA in well-powered studies of over 100 cases considered [11–17]. However, only very small studies (less than 50 cases) have examined they rate of EGFR mutations in USA H/Ls [18]. …”

Section: Introductionmentioning

confidence: 99%

Lung Cancer Mutations and Use of Targeted Agents in Hispanics

Cress¹,

Chiappori²,

Santiago³

et al. 2015

RRCT

View full text Add to dashboard Cite

Hispanic/Latinos (H/L) are expected to grow to over 24% of the USA population by 2050 and lung cancer is the number one cause of cancer death among H/L men. Due to the information that is becoming available via genetic testing, lung cancer molecular profiling is allowing for increasing application of personalized lung cancer therapies. However, to benefit the most people, development of these therapies and genetic tests must include research on as many racial and ethnic groups as possible. The purpose of this review is to bring attention to the fact that the mutations driving lung cancer in H/Ls differ in frequency and nature relative to the non-Hispanic White (WNH) majority that dominate current databases and participate in clinical trials that test new therapies. Clinical trials using new agents targeting genetic alterations (driver mutations) in lung cancer have demonstrated significant improvements in patient outcomes (for example, gefitinib, erlotinib or crizotinib for lung adenocarcinomas harboring EGFR mutations or EML4-ALK fusions, respectively). The nature and frequencies of some lung cancer driver mutations have been shown to be considerably different among racial and ethnic groups. This is particularly true for H/Ls. For example, several reports suggest a dramatic shift in the mutation pattern from predominantly KRAS in a WNH population to predominantly EGFR in multiple H/L populations. However, these studies are limited, and the effects of racial and ethnic differences on the incidence of mutations in lung cancer remain incompletely understood. This review serves as a call to address this problem.

show abstract

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

Steuer

Behera

Berry

et al. 2015

Cancer

View full text Add to dashboard Cite

BACKGROUND The discovery of oncogenic drivers has ushered in a new era for lung cancer, but the role of these mutations in different racial/ethnic minorities is understudied. The Lung Cancer Mutation Consortium 1 (LCMC1) database was investigated to evaluate the frequency and impact of oncogenic drivers in lung adenocarcinomas in the racial/ethnic minority patient population. PATIENTS AND METHODS Patients with metastatic lung adenocarcinomas from 14 United States sites enrolled in the LCMC1. Tumor samples were collected from 2009 through 2012, with multiplex genotyping performed on 10 oncogenic drivers (KRAS, EGFR, ALK rearrangements, ERBB2 (formerly HER2), BRAF, PIK3CA, MET amplification, NRAS, MEK1, AKT1). Patients were classified as Caucasian, Asian, African-American (AA), and Latino. Driver mutation frequency, treatments, and survival from diagnosis were determined. RESULTS 1007 patients were included. Caucasians represented the majority with N=838, AA N=60, Asians N=48, and Latinos N=28. Asian patients had the highest rate of oncogenic drivers with 39 (81%), followed by Latinos 19 (68%), Caucasians 511 (61%) and AA 32 (53%). In AA, EGFR mutation frequency was 22%, KRAS 17%, and ALK 4%. Asian patients were most likely to receive targeted therapies (51%), compared to 27% in AA. There were no significant differences in overall survival. CONCLUSIONS Differences are observed in the prevalence of oncogenic drivers in lung adenocarcinomas and consequent treatments among racial groups. The lowest frequency of drivers was seen in AA patients; however, over half of AA patients had a driver and those treated with targeted therapy outcomes similar to those of other races.

show abstract

EGFRMutations in US Hispanic Versus Non-Hispanic White Patients With Lung Adenocarcinoma

Cited by 16 publications

References 22 publications

EGFR Mutations in Latinos From the United States and Latin America

EGFR Mutations in Latinos From the United States and Latin America

Lung Cancer Mutations and Use of Targeted Agents in Hispanics

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

Contact Info

Product

Resources

About